摘要
目的观察布地奈德联合特布他林雾化吸入治疗小儿喘息性支气管肺炎的效果。方法选择高唐县人民医院2016年11月-2017年11月收治的88例喘息性支气管肺炎患儿,随机分为对照组和观察组各44例,对照组予以常规治疗,观察组给予布地奈德+特布他林治疗,比较两组治疗效果。结果观察组治疗后FEV1、FVC、PEF高于对照组;观察组患儿咳嗽、咳痰、喘息、发热消失时间及住院时间均短于对照组;观察组有效率为97.73%,高于对照组的70.45%,差异均有统计学意义(P<0.05);两组不良反应率差异无统计学意义(P>0.05)。结论采用布地奈德联合特布他林雾化吸入治疗小儿喘息性支气管肺炎,可缩短疗程,改善患儿的肺功能,提高治疗有效率,不良反应率低,值得临床推广。
Objective To observe efficacy of budesonide and terbutaline atomization and inhalation in the treatment of children with asthmatic bronchopneumonia. Methods Eighty-eight children with asthmatic bronchopneumonia admitted to Gaotang Country People's Hospital from November 2016 to November 2017 were selected and randomly divided into control group and observation group with 44 cases in each group.The control group was given routine treatment,and the observation group was given budesonide + terbutaline treatment. The therapeutic effect of two groups were compared. Results After treatment,FEV1,FVC and PEF in observation group were higher than those in control group; The disappearance time of cough,expectoration,wheezing,fever and hospitalization time in the observation group were shorter than those in the control group; The effective rate of the observation group was 97.73%,which was higher than 70.45% of the control group; The differences were statistically significant(P<0.05). There was no significant difference in the rate of adverse reactions between the two groups(P >0.05). Conclusion Budesonide combined with terbutaline atomization and inhalation in the treatment of children with asthmatic bronchial pneumonia can shorten treatment course,improve children lung function,improve the efficiency of treatment and reduce the rate of adverse reactions. It is worthy of clinical promotion.
引文
[1]陈洪.婴幼儿喘息性支气管肺炎潮气呼吸肺功能及血清Th1/Th2细胞因子水平变化[J].山东医药,2018,58(22):61-62.
[2]江才华.普米克令舒联合特布他林雾化吸入对小儿喘息性支气管肺炎的疗效观察[J].中国现代医生,2018,56(14):55-57.
[3]苌俊明,宋雪民.布地奈德联合氢化可的松治疗小儿喘息性支气管肺炎的临床研究[J].现代药物与临床,2017,32(12):2387-2391.
[4]叶梅.不同时期喘息性支气管肺炎患儿潮气呼吸功能检查的临床价值[J].中国现代药物应用,2017,11(17):24-26.
[5]关航航.雾化吸入治疗小儿喘息性支气管肺炎的配合护理干预[J].首都食品与医药,2018,25(21):1.